您搜索了: palivizumaba (斯洛文尼亚语 - 英语)

ena 1 ml viala vsebuje 100 mg palivizumaba.
each 1 ml vial contains 100 mg of palivizumab.

3 x 15 = 0, 45 ml palivizumaba na mesec.
3 x 15 = 0.45 ml palivizumab dose per month.

vsaka 1 ml viala vsebuje 100 mg palivizumaba.
each 1 ml vial contains 100 mg of palivizumab.

vsaka 0,5 ml viala vsenbuje 50 mg palivizumaba.
each 0.5 ml vial contains 50 mg of palivizumab.

palivizumaba se ne sme mešati z drugimi zdravili ali topili.
palivizumab should not be mixed with any medicinal products or diluents.

1 ml raztopine zdravila synagis vsebuje 100 mg palivizumaba*.
1 ml of synagis solution contains 100 mg of palivizumab*.

koncentracija po navodilu pripravljene raztopine palivizumaba je 100 mg/ ml.
each vial contains 50 mg palivizumab, providing 100 mg/ ml of palivizumab when reconstituted as recommended.

1 ml zdravila synagis raztopina za injiciranje vsebuje 100 mg palivizumaba.
one ml of synagis solution for injection contains 100 mg of palivizumab.

med obdobjem pomarketinške uporabe palivizumaba so bili opisani naslednji pojavi:
the following events were reported during post-marketing experience of palivizumab:

100 mg palivizumaba; koncentracija po navodilu pripravljene raztopine je 100 mg/ ml.
100 mg palivizumab, providing 100 mg/ ml of palivizumab when reconstituted as recommended.

raztopina palivizumaba mora stati na sobni temperaturi vsaj 20 minut, dokler se ne zbistri.
palivizumab solution should stand at room temperature for a minimum of 20 minutes until the solution clarifies.

- vsaka viala vsebuje 100 mg palivizumaba; koncentracija po navodilu pripravljene raztopine je
- each vial contains 100 mg palivizumab, providing 100 mg/ml of palivizumab when

palivizumaba se ne sme mešati z nobenim drugim zdravilom in nobenim drugim vehiklom kot z vodo za injekcije.
palivizumab should not be mixed with any medicinal products or diluents other than water for injections.

dve ločeni raziskavi varnosti palivizumaba, uporabljenega v drugi sezoni rsv, sta zajeli skupno 222 otrok.
a total of 222 children were enrolled in two separate studies to examine the safety of palivizumab when it is administered for a second rsv season.

le redko je bilo treba uporabo palivizumaba zaradi neželenih učinkov dokončno prekiniti (0, 2%).
permanent discontinuation of palivizumab due to adrs was rare (0.2%).

blaga vročinska bolezen, npr. blaga okužba zgornjih dihal, ponavadi ni razlog za odložitev uporabe palivizumaba.
a mild febrile illness, such as mild upper respiratory infection, is not usually reason to defer administration of palivizumab.

priporočeni odmerek palivizumaba je 15 mg/kg telesne mase enkrat na mesec med predvidenimi obdobji tveganja za rsv v otrokovem okolju.
the recommended dose of palivizumab is 15 mg/kg of body weight, given once a month during anticipated periods of rsv risk in the community.

učinkovitost palivizumaba v odmerkih drugačnih od 15 mg na kg ali pri odmerjanju, ki je drugačno od enkrat mesečno, med sezono rsv ni bila dokazana.
the efficacy of palivizumab at doses other than 15 mg per kg or of dosing differently from monthly throughout the rsv season, has not been established.

v primeru zmerne do hude akutne okužbe ali vročinske bolezni je treba uporabo palivizumaba odložiti, razen če ta odlog po zdravnikovi presoji pomeni večje tveganje.
a moderate to severe acute infection or febrile illness may warrant delaying the use of palivizumab, unless, in the opinion of the physician, withholding palivizumab entails a greater risk.

učinkovitost palivizumaba pri bolnikih, ki ga dobijo v ponovnem ciklusu naslednjo sezono rsv, ni bila formalno preskušena v kakšni študiji, opravljeni s tem namenom.
the efficacy of palivizumab when administered to patients as a second course of treatment during an ensuing rsv season has not been formally investigated in a study performed with this objective.